ADARx Pharmaceuticals (ADRX) News
NASDAQ: ADRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADRX news summary
We found 3 recent headlines mentioning ADARx Pharmaceuticals (ADRX): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. ADRX is making an outsized move today, down 9.68% at $12.79, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "ADARx Advances Agazisiran, Onvuzosiran Programs; Key Clinical Readouts Set For 2027", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ADARx Pharmaceuticals headlines
- ADARx Advances Agazisiran, Onvuzosiran Programs; Key Clinical Readouts Set For 2027(RTTNews) - ADARx Pharmaceuticals, Inc. (ADRX), a late-clinical-stage biotechnology company, reported third-quarter 2026 financial results and highlighted progress across its siRNA therapeutic…NasdaqADRX, BRK.A
- ADARx Pharmaceuticals reports Q3 resultsSeeking Alpha
- ADARx Pharmaceuticals to Present at the UBS Global Biopharma ConferenceADARx Pharmaceuticals to Present at the UBS Global Biopharma ConferenceGlobeNewswire